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Importance:AdultswithDown syndrome (DS) are at high-risk of revealingAlzheimer’s
disease (AD) pathology, in part due to the triplication of chromosome 21 encoding the
amyloid precursor protein. Adults with DS are uniformly affected by AD pathology by
their 30′s and have a 70% to 80% chance of clinical dementia by their 60′s. Our pre-
vious studies have assessed longitudinal changes in amyloid beta (Aβ) accumulation in
DS.
Objective: The goal of the present study was to assess the presence of brain tau using
[18F]AV-1451 positron emission tomography (PET) inDS and to assess the relationship
of brain tau pathology to Aβ using Pittsburgh Compound B (PiB)-PET.
Design:Cohort study
Setting:Multi-center study
Participants: Participants consisted of a sample of individuals with DS and sibling
controls recruited from the community; exclusion criteria included contraindications
for magnetic resonance imaging (MRI) and/or a medical or psychiatric condition that
impaired cognitive functioning.
Exposures: PET brain scans to assess Aβ ([11C]PiB) and tau ([18F]AV-1451) burden.
Mainoutcomes andmeasures:Multiple linear regressionmodels (adjusted for chrono-
logical age, sex and performance site) were used to examine associations between
regional [18F]AV-1451 standard uptake value ratio (SUVR) (based on regions asso-
ciated with Braak stages 1-6) and global [11C]PiB SUVR (as both a continuous and
dichotomous variable).
Results: A cohort of 156 participants (mean age = 39.05, SD(8.4)) were examined.
These results revealed a significant relationship between in vivo Aβ and tau pathol-
ogy inDS. As a dichotomous variable, [18F]AV-1451 retentionwas higher in eachBraak
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published byWiley Periodicals LLC on behalf of Alzheimer’s Association
Alzheimer’s Dement. 2020;6:e12096. wileyonlinelibrary.com/journal/trc2 1 of 8
https://doi.org/10.1002/trc2.12096
2 of 8 TUDORASCU ET AL.
region in PiB(+) participants. We also found, based on our statistical models, starting
with the Braak 3 region of interest (ROI), an acceleration of [18F]AV-1451 SUVR depo-
sition with [11C]PiB SUVR increases.
KEYWORDS
Down syndrome, PET amyloid, TAU, Alzheimer’s disease
1 INTRODUCTION
Definitive diagnosis of Alzheimer’s disease (AD) relies on the demon-
stration of amyloid beta (Aβ) plaques and tau-containing neurofibril-
lary tangles at autopsy.1,2 More recently, the availability of positron
emission tomography (PET) ligands for Aβ, such as [11C]PiB3 and for
tau, such as [18F]AV-14514 have allowed in vivo examination of the
relationship of cognition to AD pathophysiology. These studies have
demonstrated that tau pathology is more closely related to cogni-
tive decline than Aβ2 and is associated with AD diagnosis,5 amyloid
positivity,6 and cognitive function.7
Adults with Down syndrome (DS) are uniformly affected by AD-
related pathology, characterized by the presence ofAβ plaques by their
fourth decade (Wisniewski 1985; Hyman 1992; Lemere 1996), and
they demonstrate an increased prevalence of AD. From a large body of
data, it is clear that overproduction of amyloid precursor protein (APP),
in part due to the triplication of chromosome 21 encoding APP, is asso-
ciated with a high risk of AD in DS and the appearance of clinical AD at
an earlier age.8,9
AβPETstudies inDShave identified adistinct pattern amyloiddepo-
sition, beginning predictably inmid-life,10,11 which has been confirmed
in an autopsy study ofDS.12,13 TauPET studies inDS are relatively new,
with only one small study (n=12) demonstrating increasing tau burden
with age and amyloid positivity and a correlation between tau burden
and cognitive impairment,14 mimicking the findings observed in late-
onset AD using [18F] AV-1451.5 Based on these data, we hypothesize
that higher regional Aβ measured by PiB-PET will be associated with
increased neurofibrillary tangles (NFTs) measured using AV-1451 PET.
This cross-sectional PET study aims to assess in DS the relationship
of global Aβ to regional neurofibrillary tangles (NFTs) characterized by
Braak staging.
2 METHODS
2.1 Study design and participants
All participants, n = 156 (135 DS and 21 controls), mean age = 39.05
(SD= 8.4) underwent [11C]PiB and [18F]AV-1451 scans as well as clin-
ical and neuropsychological examination. All participants had a clini-
cal diagnosis based on consensus case conference. The consensus for
our 135DS participantswas as follows: 108were non-demented, non–
mild cognitive impaired (MCI), 8 had a clinical diagnosis ofMCI, 11 had
a diagnosis of dementia, and for 8 participants the clinical consensus
was unable to determine a diagnosis.15 Based on our published PiB
thresholds,16 all of our participants were categorized as DS-PiB(−) or
DS-PiB(+); briefly, any DS participant with PiB regional values exceed-
ing the threshold in at least one region of the six regions measured
(anterior cingulate, frontal cortex, striatum, precuneus, lateral tempo-
ral, and parietal cortices) is defined as DS-PiB(+). In addition, we also
included a sibling-control sample; all were classified as PiB(−).
Image Acquisition Imaging data were acquired at four sites: The
University of Pittsburgh using a Siemens Prisma (magnetic resonance
imaging; MRI) and a Siemens mCT Biograph (PET), the University of
Wisconsin-Madison using a General Electric Discovery MR750 (MRI)
and a SiemensHR+ (PET), theUniversity of Cambridge using aGeneral
Electric SIGNAPET/MR (MRIandPET), andBannerHealthusingaGen-
eral Electric Discovery MR750 (MRI) and a General Electric Discovery
710 (PET). T1-weightedMR images were acquired for each subject for
anatomical reference.
PET tracers (15 mCi [11C]PiB or 10 mCi [18F]AV-1451, nominal)
were administered as bolus injections, over approximately 30 seconds,
followed by a saline flush. Subjects were imaged over time ranges that
included 50-70minutes post-injection for the case of [11C]PiB and 80-
100minutes post-injection for the case of [18F]AV-1451. For each sub-
ject, [18F]AV-1451 scans were obtained in time proximity and, most
frequently, on the same day following the [11C]PiB scans.
PET images were reconstructed into 45-minute time frames span-
ning the range 50-70 minutes post-injection ([11C]PiB) or 80-100
minutes post-injection ([18F]AV-1451). Image reconstruction was per-
formed using the manufacturer’s software and included correc-
tions for scatter, deadtime, random coincidences, and radioactive
decay.
2.2 Image processing
ThemultiframePET imageswere visually inspected for frame-to-frame
motion. If necessary, motion correction was performed using a set
of stable frames (averaged) as a reference. Frames requiring correc-
tion were registered to the reference using PMOD. Single-frame PET
imageswere formedby averaging over the50-70minute post-injection
frames for PiB and over 80-100 minutes for AV-1451. Each subject’s
MRI was manually aligned to anterior-commissure/posterior commis-
sure (ACPC) orientation. The single-frame PET images (PiB and AV-
1451) were registered to this using the registration tool of PMOD
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(https://www.pmod.com/web/) via maximization of normalized mutual
information.
Each subject’s T1 MRI was parcellated into regions of interest
(ROIs) using FreeSurfer v5.3. The standard FreeSurfer pipeline was
used for this procedure and modified to obtain a more finely detailed
parcellation of the striatum than that produced by FreeSurfer with
the built-in Desikan-Killiany (DK) atlas. We incorporate the Clini-
cal Imaging Center (CIC) atlas,17 developed for dopamine imaging,
into our analysis. The T1 MRI associated with CIC atlas was pro-
cessed through FreeSurfer using the standard pipeline, providing a
transformation that can be used to put the CIC atlas into internal
FreeSurfer space. The net result of the procedure is that any scan
processed through FreeSurfer can be labeled with the CIC regions as
well as the FreeSurfer/DK regions. With this capability, subject scans
were parcellated into FreeSurfer/DK regions, except that the stria-
tum was parcellated using CIC atlas regions. Specifically, the set of
FreeSurfer DK regions (right and left) caudate, putamen, and pallidum
were replaced by the set of CIC atlas regions (right and left) ventral
striatum, dorsal caudate, posterior caudate, anterior putamen, pos-
terior putamen, and pallidum. All FreeSurfer results were inspected
and, if necessary, edited for proper anatomical alignment with the
MRI.
For some subjects, however, the raw FreeSurfer (FS) results were
inadequate, even for editing. Based onwork reported by Svarer et al.,18
some of these cases were salvaged using an approach in which scans
that were successfully parcellated by FreeSurfer were used as tem-
plates for the problematical scans. Briefly, a template ensemble was
assembled using 12 subjects (10 DS and 2 controls) from the Neurode-
generation in Aging Down Syndrome (NiAD) population with existing
high-quality FS-basedparcellations. All of theT1 template imageswere
skull stripped using the tissue segmentation function of SPM12 (Statis-
tical Parametric Mapping, www.fil.ion.ucl.ac.uk/spm/software/spm12).
Voxels with a combined probability of being white matter, gray mat-
ter, or cerebrospinal fluid of >0.0001 were classified as brain tissue
and retained in the image. Next, the T1MR image from each subject to
be processed was skull stripped using the procedure described for the
templates. For a given subject, each of the 12 template T1 MR images
was warped to the skull-stripped subject image using the “Normalize”
function of SPM8, and the existing FS parcellations were carried along
using the templates’ warping parameters. Using this method, for each
FS region, 12 ROI images warped to the subject’s MRI were produced.
A “probability image” was then generated by averaging the 12 individ-
ual template ROI images. The final probability-template ROI for the
regionwas constructed by selecting voxels with the highest probability
until a volumewas achieved thatwas equal to the volumeof that region
averaged over the 12 warped templates. This process was repeated
for every FS region resulting in a full set of FS-ROIs for each subject.
Final results were inspected and either accepted or rejected, but no
ROI editing was performed. Of 156 participants this method was uti-
lized only on 20 participants, all in the DS group.
For each subject, PET activity images (registered with the MRI)
were sampled using the ROIs determined as described above either
using standard FS or our probability template method. Regional values
HIGHLIGHTS
∙ Question: The goal of this studywas examine the relation-
ship between amyloid and tau burden in Down syndrome
(DS).
∙ Findings: In this multi-center population-based cohort
study of DS we observed a significant relationship
between in vivo amyloid beta (Aβ) and tau pathology in
DS, similar to that seen in the typical aging population.We
also found, based onour statisticalmodels, an acceleration
of [18F]AV-1451 SUVR deposition with [11C]PiB SUVR
increases.
∙ Meaning: These data add to the existing body of literature
in DS to contribute to providing the necessary framework
to identify appropriate participants for clinical trials, track
efficacy of interventions, and track dementia progression
in the DS population.
were normalized by dividing by cerebellar gray matter activity, deter-
mined using a volume-weighted average of activity obtained using the
FreeSurfer left and right cerebellar cortex ROIs. The result is a set of
cerebellum gray matter normalized tissue ratios (standardized uptake
value ratios, SUVRs) for each ROI and tracer.
A global region for amyloid status (positive or negative) was
composed from the region’s anterior cingulate, superior frontal,
orbitofrontal, insula, lateral temporal, parietal posterior cingulate, pre-
cuneus, putamen, and striatum. The FreeSurfer and CIC atlas regions
from which these are composed are listed in Supplemental Table S1.
Parenthetically, because of the observation that the striatum of DS
subjects showsdifferent patterns of amyloid deposition than in non-DS
sporadic AD, a larger striatal regionwas used inDS studies than in non-
DS. See Supplemental Table S1.1 and S1.2 for details. [11C]PiB SUVRs
were determined for each of these super regions and ultimately for the
global region via a volume-weighted average of the SUVRs of the com-
ponent regions. Scans were defined to be amyloid positive, PiB (+), or
negative PiB (−), based on a global SUVR threshold of 1.36.
Six Braak super regions (Braak regions) corresponding to the six
Braak stages19 were used for the quantitation of [18F]AV-1451. The
Braak region SUVRs were determined from a volume-weighted aver-
age of SUVRs in sets of FreeSurfer regions described in Schöll et al.,20
except that the striatumwas not included in Braak region 5. The Braak
regions are exclusive in that, for example, Braak region 2 does not
include Braak region 1, and so on. As in the case of [11C]PiB, [18F]AV-
1451 SUVRs are normalized by cerebellar graymatter.
2.3 Statistical methods
Descriptive statistics (means and standard deviations) are presented
for age and for each Braak Region by DS-PiB (−), DS-PiB (+), and
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RESEARCH INCONTEXT
1. Systematic review: Tau positron emission tomography
(PET) studies in Down syndrome (DS) are relatively
new, with only one small study (n = 12) demonstrat-
ing increasing tau burden with age and amyloid posi-
tivity and a correlation between tau burden and cog-
nitive impairment; however, this study was preliminary
in nature. No studies have been undertaken to exam-
ine the relationship between amyloid and tau burden in
DS. Our findings demonstrate a significant relationship
between in vivo amyloid beta (Aβ) and tau pathology in
DS, similar to those seen in the typical aging popula-
tion. As a dichotomous variable, [18F]AV-1451 retention
was higher in each Braak region in PiB(+) participants.
We also found, based on our statistical models, starting
with the Braak 3 region of interest (ROI) an acceleration
of [18F]AV-1451 SUVR deposition with [11C]PiB SUVR
increases.
2. Interpretation: These findings are among the first to
report tau pathology using PET in DS and are, to our
knowledge, the largestDS cohort using tau-PET.Our find-
ings suggest that tau pathology inDS does not differ from
that of late-onset AD, with tau pathology increasing in
regions associatedwithBraak regions in thosewith signif-
icant amyloid pathology. These data track with pathologi-
cal studies in DS that have not identified clear differences
in neurofibrillary tau deposition from late-onset AD, but
unlike these neuropathological studies are not restricted
to those with late-stage disease in all groups. In addition,
these data extend our previous findings, identifying a dis-
tinct pattern of predominant striatal Aβ deposition that
distinguished theAβdeposition seen in late-onsetADand
DS into tau pathology in DS.
3. Future directions: These data adding to the existing body
of literature in DS contribute to providing the necessary
framework to identify appropriateparticipants for clinical
trials, track efficacy of interventions, and track dementia
progression in the DS population.
Controls-PiB (−) in Table 1. Frequency percentages are shown for sex
and consensus diagnosis (Table 1).
To assess differences among DS-PiB(−), DS-PiB(+), and Controls-
PiB(−), multiple linear regression models were used with dummy cod-
ing (0/1) for the groups and performance sites (group 1 is the DS-PiB
(+), group 2 is the DS-PiB (−), and Controls-PiB (−) are the reference
category) for eachBraakROI. The linearmodel used for eachBraakROI
is presented below:
yi = 𝛽0 + 𝛽1Groupi1 + 𝛽2Groupi2 + 𝛽3Sitei1 + 𝛽4Sitei2 + 𝛽5Sitei3 + 𝜀i ,
(1)
where:
i) 𝛽0 represents the intercept (average Braak ROI SUVR value over
the whole sample, for each ROI respectively);
ii) Groupi is the dummy variable for group factor for subject i,
and 𝛽1 coefficient represents the difference in the mean of tau
SUVR between the DS-PiB (+) subjects compared to the controls,
whereas 𝛽2 represents the difference in the mean of Tau SUVR
between the DS-PiB (−) subjects compared to the controls, taking
into the account the effect of site.
iii) Sitei is the dummy variable for site factor for subject i, and the
𝛽3, 𝛽4, and 𝛽5 coefficients for site represent the differences in the
mean of tau SUVRbetween that specific site and the reference site
when groups are fixed.
Controls are considered to be the reference category for groups
and the site variable is included to account for variability due to data
being collected at multiple sites (with UK as the reference site). The
samemodel was rerun including age at scan and all the results are pre-
sented in Table 2 in the form of mean differences between the groups
along with 95% confidence interval (CI), unadjusted (model 1) as well
as adjusted for age at scan (model 1+age). Based on the examination of
scatter and LOESS (locallyweighted scatterplot smoothing) plots of tau
SUVR as a function of Global PiB SUVR and guided by F-tests, we con-
sidered either linear or quadratic models for Braak ROIs 1 through 6.
TheF-testswere performed to test if the addition of the quadratic term
significantly added to explaining the variability in the model. Based on
these evaluations, we used only a linear term for Braak ROIs 1 and 2
(model 2) and added a quadratic term for Braak ROIs 3, 4, 5, and 6
(model 3) withmodel terms described above.
yi = 𝛽0 + 𝛽1PiB_SUVRi + 𝛽2Sitei1 + 𝛽3Sitei2 + 𝛽4Sitei3 + 𝜀i (2)
and
yi = 𝛽0 + 𝛽1PiB_SUVRi + 𝛽2 PiB_SUVR
2
i + 𝛽3Sitei1
+𝛽4Sitei2 + 𝛽5Sitei3 + 𝜀i (3)
The regression coefficient estimates along with 95% CI unadjusted
(model 2 and 3) and adjusted for age (model 2 and 3 including age) are
presented in Table 3. These estimates can be considered as effect sizes,
since they represent the amount of change in tau SUVR for each one-
unit change in PiB SUVRwhen site and age are fixed.
All of the above analyses were repeated for the DS-PiB(+) only,
and the results are presented in supplemental Table 2S and supple-
mental Figure 1S. None of our analyses were corrected for multiple
comparisons.
3 RESULTS
In this cohort, we had 76 male and 80 female participants, with an
average age of 39.04 (SD = 9.00). The DS-PiB (+) participants had
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TABLE 1 Descriptive statistics for groups for each Braak ROI







Consensus Dx 0= no
MCI/no dementia
0 (108) NA 0 (71) 0 (37)
1=MCI 1(8) 1 (0) 1 (8)
2= dementia 2 (11) 2 (0) 2 (11)
3= unable to determine 3 (8) 3 (2) 3 (6)
Sex M (76, 48%) M (5, 24%) M (36, 38%) M (35, 56%)
Age at AV-1451 scan 39.04 (9.00) 39.00 (12.46) 33.61(4.80) 45.45 (7.15)
Braak Region 1 1.23 (0.22) 1.12 (0.07) 1.14 (0.10) 1.38 (0.27)
Braak Region 2 1.17 (0.21) 1.06 (0.13) 1.09 (0.10) 1.31 (0.26)
Braak Region 3 1.18 (0.25) 1.09(0.05) 1.10 (0.06) 1.30 (0.36)
Braak Region 4 1.14 (0.21) 1.08(0.07) 1.08 (0.07) 1.25 (0.29)
Braak Region 5 1.12 (0.25) 1.04 (0.06) 1.04 (0.06) 1.23 (0.36)
Braak Region 6 1.05 (0.21) 1.00 (0.08) 1.00 (0.06) 1.10 (0.30)





and 95%CI (age adjusted)
Braak 1 DS-PiB (+) vs Controls-PiB (−) 0.23 (0.13, 0.32) 0.19 (0.10, 0.30)
DS-PiB (−) vs Controls-PiB (−) −0.01(−0.10, 0.08) 0.01 (−0.08, 0.11)
DS-PiB (+) vs DS-PiB (−) 0.24 (0.18, 0.30) 0.18 (0.11, 0.26)
Braak 2 DS-PiB (+) vs Controls-PiB (−) 0.25 (0.15, 0.34) 0.20 (0.10, 0.29)
DS-PiB (−) vs Controls-PiB (−) 0.02 (−0.07, 0.11) 0.06 (−0.03, 0.15)
DS-PiB (+) vs DS-PiB (−) 0.22 (0.16, 0.29) 0.14 (0.06, 0.22)
Braak 3 DS-PiB (+) vs Controls-PiB (−) 0.20 (0.08, 0.32) 0.15 (0.03, 0.27)
DS-PiB (−) vs Controls-PiB (−) −0.006 (−0.12, 0.11) 0.03 (−0.08, 0.15)
DS-PiB (+) vs DS-PiB (−) 0.21 (0.13, 0.29) 0.12 (0.02, 0.22)
Braak 4 DS-PiB (+) vs Controls-PiB (−) 0.17 (0.07,0.27) 0.12 (0.02, 0.22)
DS-PiB (−) vs Controls-PiB (−) −0.002 (−0.10,0.09) 0.04 (−0.06, 0.13)
DS-PiB (+) vs DS-PiB (−) 0.17 (0.11, 0.24) 0.08 (0.003, 0.16)
Braak 5 DS-PiB (+) vs Controls-PiB (−) 0.18 (0.06, 0.30) 0.14 (0.02,0.27)
DS-PiB (−) vs Controls-PiB (−) −0.002 (−0.12,0.12) 0.03 (−0.09, 0.15)
DS-PiB (+) vs DS-PiB (−) 0.19 (0.12, 0.26) 0.12 (0.02, 0.22)
Braak 6 DS-PiB (+) vs Controls-PiB (−) 0.10 (−0.006, 0.20) 0.08 (−0.02, 0.19)
DS-PiB (−) vs Controls-PiB (−) −0.002 (−0.10,0.10) 0.006 (−0.10, 0.11)
DS-PiB (+) vs DS-PiB (−) 0.10 (0.03, 0.17) 0.08 (−0.007, 0.17)
Note : Second column shows the estimated mean differences in AV-1451 SUVR between groups adjusted for site, and third column shows the differences
adjusted for site and age at scan.
an average age of 45.45 (SD = 7.15) years and the DS-PiB (−) had an
average age of 33.61 (SD= 4.80). The average Braak ROIs were higher
for DS-PiB (+) than for the DS-PiB (−) or Control-PiB (−). These values
were higher for lower Braak ROIs starting at 1.14 (SD = 0.10) for the
DS-PiB (−) in Braak 1 ROI and decreasing to a value of 1.00 (0.06) in
Braak 6 ROI. Similarly, the DS-PiB (+) starts at an average value of
1.38 (SD = 0.27) in Braak 1 ROI SUV (see Table 1). The Control-PiB(−)
mean values are similar to the DS-PiB (−) mean values (see Table 1).
Using the multiple linear regression model, (equation 1), we found
differences between DS-PiB (+) and DS-PiB (−) as well as between
DS-PiB (+) and Control-PiB (−), and they are very close in magnitude.
These differences are presented in Table 2. It can be observed that the
magnitude of the differences between DS-PiB (+) and DS-PiB (−) is
lower for higher Braak ROIs (ranging from 0.24, 95% CI [0.18, 0.30]
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Braak 1 0.57(0.43, 0.72) 0.52(0.44, 0.60) NA
Age adjusted 0.57(0.41, 0.63) 0.51(0.40,0.63) NA
Braak 2 0.55(0.42, 0.69) 0.50(0.42, 0.57) NA
Age adjusted 0.53(0.38, 0.69) 0.47(0.37, 0.58) NA
Braak 3 1.33(0.93, 1.75) −0.70(−1.22,−0.19) 0.43(0.27, 0.59)
Age adjusted 1.29(0.86, 1.72) −0.58(−1.22, 0.06) 0.40(0.22, 0.58)
Braak 4 1.11(0.75, 1.47) −0.33(−0.78, 0.13) 0.27(0.13, 0.41)
Age adjusted 1.09(0.71, 1.47) −0.29(−0.85, 0.28) 0.26(0.10, 0.42)
Braak 5 1.71(1.32, 2.11) −1.24(−1.74,−0.73) 0.59(0.43, 0.74)
Age adjusted 1.62(1.20, 2.04) −0.98(−1.60, 0.36) 0.52(0.35, 0.70)
Braak 6 2.11(1.73, 2.50) −1.73(−2.22,−1.24) 0.67(0.52, 0.82)
Age adjusted 1.97(1.57, 2.37) −1.35(−1.94,−0.76) 0.58(0.41, 0.75)
in Braak 1 ROI, lower in Braak 4 ROI (0.17, 95% CI [0.11, 0.24]) and
much lower in Braak 6 ROI (0.10, 95% [0.03, 0.17]). We found that the
differences between DS-PiB (+) and DS-PiB (−) in Braak 2 and 3 ROIs
were very close to each other. All these differences became lower
when themodels were adjusted for age at scan (Table 2).
Theassociationsbetween tauSUVRandPiBSUVRwere in the range
of moderate effect sizes for most of the coefficients. A linear associa-
tion was found between tau SUVR in Braak 1 ROI, β= 0.52 (0.44, 0.60)
and Braak 2, β = 0.50 (0.42, 0.57), suggesting that for each one unit
increase in Global PiB SUVR there is a 0.52 increase in tau SUVR for
Braak 1 and a 0.50 increase in tau SUVR for Braak 2. Similar effects
were determined when models were additionally adjusted for age.
These values were determined from the coefficients of PiB SUVR from
model 2 and are presented in Table 3.
Starting with the Braak 3 ROI, we have found an acceleration of tau
SUVR deposition with PiB SUVR increase. This acceleration is deter-
mined by the coefficient of the quadratic PiB SUVR term. Using model
3, this coefficient gives information with respect to the direction and
the steepness of the relationship between these variables. All of the
associations that were found were convex (a positive curvature), with
lower coefficients for Braak 3ROI (0.43, 95%CI [0.27, 0.59]) andBraak
4 ROI (0.27, 95% CI [0.13, 0.41]) and higher quadratic coefficients in
Braak 5 ROI (0.59, 95% CI [0.43, 0.74]) and Braak 6 ROI (0.67, 95% CI
[0.52, 0.82]).Mathematically, this indicates that, asPiBSUVR increases,
the tau amyloid changes by 𝛽1 + 2𝛽2PiB_SUVR (the derivative of the
quadratic model 3 with respect to the Global PiB SUVR). For example,
for a valueofGlobal-PIBSUVRequal to1.5, the estimatedTAUSUVR in
Braak 3 ROIwill be 1.8 (-0.70+2*0.43*1.5= 1.8, Table 3). For a value of
Global-PiB SUVR equal to 2.5, the estimated tau SUVR in Braak 6 will
be 1.62 (-1.73+2*0.67*1.25= 1.62).
The plots showing the linear and the quadratic associations are pre-
sented in Figure 1.
4 DISCUSSION
The recent development of tau-PET ligands has provided the unique
opportunity to expand our knowledge of the natural history of AD
pathophysiology in DS. These data extend our previous findings, iden-
tifying a distinct pattern of predominant striatal Aβ deposition that dis-
tinguished the Aβ deposition seen in late-onset AD and DS21 into tau
pathology inDS. These finding are among the first to report tau pathol-
ogy using PET in DS and are, to our knowledge, the largest DS cohort
using tau PET.
These results demonstrate a significant relationship between in vivo
Aβ and tau pathology in DS, similar to those seen in the typical aging
population. Thedifferencesobservedbetweenamyloid-positivepartic-
ipants with DS and amyloid-negative participants with DS or amyloid-
negative controls decreased in regions associated with the highest
Braak stages. This decreasing difference is likely a result of lower over-
all tau pathology in Braak stages 5 and 6, given that the majority of
the participants in this study were non-demented and early in the time
course of AD pathophysiology. One limitation of the current study is
that themajorityof theDSparticipants are classifiedas cognitivelynor-
mal and were middle aged (39.04 years); expanding both the age and
cognitive function range of this cohort will be essential to understand-
ing the full spectrum of AD.
Although we observed decreasing differences in overall tau pathol-
ogy in regions associated with higher Braak stages, our quadratic mod-
els suggest an acceleration of tau pathology in regions associated with
higher Braak stages as amyloid pathology increases. Indeed in Braak
ROIs 5 and 6, the quadratic coefficient indicates a steeper increase
(0.59 in Braak 5 and 0.67 in Braak 6, Figure 1) associated with accumu-
lating Aβ. Our findings suggest that tau pathology in DS does not dif-
fer from that in late-onset AD, with tau pathology increasing in regions
associated with Braak regions in those with significant amyloid pathol-
ogy. These data track with pathological studies in DS that have not
identified clear differences in neurofibrillary tau deposition from late-
onset AD, but these are restricted to patients with late-stage disease
in all groups.22–24 This model also supports the hypothesis that amy-
loid pathology is an initiating event leading to the spread of tau from
the medial temporal lobes to neocortex, increasing the rate of accu-
mulation as tau levels increase.25 However, additional longitudinal data
fromDS participants with ADwill be required to determine if ourmod-
els do in fact represent the true AD pathophysiology in DS and match
those identified in pathological studies.
Two technical limitations in the present study are the use of the
cerebellum as a reference region for [11C]PiB and the use of the 80-
100 analysis window for [18F]AV-1451 . We acknowledge the find-
ings reported in the literature of improved sensitivity with PiB using
the white matter reference region (Brendel et al., 2015; Chen et al.,
2015; Schwarz et al., 2017), particularly related to addressing the
shortcomings of technical variability introduced by differences in scan-
ner slice sensitivity and noise. However, we feel strongly that cere-
bellar gray matter reference region provides a more accurate physi-
ological representation of amyloid and tau burden. Considering that
the SUVR metric serves as a proxy for the distribution volume ratio





































































































































F IGURE 1 Models for AV-1451with Global-PiB SUVR. The plots are showing the linear and quadratic model fit lines for each Braak region
(shown on y-axes) and Global-PiB SUVR (shown on x-axes)
(DVR) or binding potential (BPND), the non-displaceable distribution
volume (V_ND = K1/k2’) should be close to equal in these gray mat-
ter tissue regions (and thus cancel out in the ratio), and that the over-
all findings would be expected to be compatible. In addition, it has
been suggested that the analyses of [18F]AV-1451 using the 80-100
minute window may underestimate the SUVR values, particularly in
the high binding range; however, in the same study it was suggested
that the 80-100 minute was best for studying the full range of tau
pathology.26
As we move toward an era of dementia prevention trials in DS, an
understanding of the natural history of AD pathophysiology in DS is
critical.27 These data do not yet provide information about the role of
tau pathology in the transition to clinical dementia; however, ongoing
collection of longitudinal cognitive and imaging data within this cohort
will provide data to answer this important question in the further.
Furthermore, these data add to our understanding of AD pathology in
DS, expanding from the large body of literature related to amyloid PET
by exploring tau PET and are an important first step in understanding
the natural history of amyloid and tau in the transition to dementia
in DS. Furthermore, these biomarker data will provide the necessary
framework to identify appropriate participants for clinical trials,
track efficacy of interventions, and track dementia progression in this
population.
5 CONCLUSIONS AND RELEVANCE
These data demonstrate that similar to late-onset AD, in vivo Aβ and
tau pathology are associated in DS. In addition, these data suggest a
higher tau pathology in regions associated with higher Braak stages
8 of 8 TUDORASCU ET AL.
as amyloid pathology increases. These finding are among the first to
report tau pathology using PET in DS and are, to our knowledge, the
largest DS cohort using tau PET. The data also contribute to providing
the necessary framework to identify appropriate participants for clin-
ical trials, track efficacy of interventions, and track dementia progres-
sion in the DS population.
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